Stocktoria
Avalo Therapeutics, Inc. AVTX
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2015-11-13
Avalo Therapeutics, Inc. financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $59,000 | $441,000 | $1.9M | $18.1M | $5.4M | $6.7M | $6.8M | $7.0M | $27.8M | $1.2M |
| R&D expense | — | — | — | — | — | — | — | $5.8M | $4.4M | $10.1M |
| SG&A expense | — | — | $10.3M | $20.7M | — | — | — | — | — | — |
| Operating income | -$72.9M | -$68.5M | -$27.4M | -$37.4M | -$82.1M | -$72.8M | -$16.1M | -$35.4M | $13.9M | -$16.1M |
| Income tax | $165,000 | $114,000 | $14,000 | $28,000 | -$196,000 | -$2.8M | $280,316 | -$49,466 | $2.0M | $0 |
| Net income | -$78.3M | -$35.1M | -$31.5M | -$41.7M | -$84.4M | -$63.5M | -$16.1M | -$40.1M | $11.9M | -$16.5M |
| EPS (diluted) | $-5.84 | $-20.91 | $-113.58 | $-1063.00 | — | — | — | $-1.20 | $0.42 | $-1.87 |
| Operating cash flow | -$51.5M | -$49.1M | -$30.7M | -$26.8M | -$70.9M | -$40.5M | -$19.1M | -$3.1M | $12.6M | -$14.6M |
| Free cash flow | — | — | — | -$26.8M | -$71.0M | -$40.6M | -$19.4M | -$3.7M | $12.6M | -$14.6M |
| Cash & equivalents | $15.9M | $134.5M | $7.4M | $13.2M | $54.6M | $18.9M | $3.6M | $10.6M | $2.5M | $5.1M |
| Inventory | — | — | $0 | $20,000 | $38,000 | $3,000 | $21,334 | $317,923 | $382,153 | $0 |
| Total assets | $116.5M | $150.7M | $21.0M | $33.4M | $80.2M | $43.8M | $36.1M | $70.3M | $42.8M | $5.8M |
| Total liabilities | $33.4M | $17.7M | $13.7M | $44.3M | $57.1M | $19.2M | $15.1M | $49.3M | $14.9M | $5.6M |
| Shareholders' equity | $83.0M | $133.0M | $7.3M | -$10.9M | $23.1M | $24.6M | $21.0M | $20.9M | $27.9M | $207,002 |
Growth · year-over-year · Revenue CAGR -28.1%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | -86.6% | -77.1% | -89.3% | +234.4% | -19.4% | -0.8% | -4.0% | -74.7% | +2312.3% | — |
| Net income growth | — | — | — | — | — | — | — | -437.4% | — | — |
| EPS growth | — | — | — | — | — | — | — | -385.7% | — | — |
| Free cash flow growth | — | — | — | — | — | — | — | -129.4% | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.